Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00098917 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Jonsson Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00098917 is a Phase 1 study that was terminated before completion, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 15 participants.
The verdict
NCT00098917, a Phase 1 study, was terminated before completion, sponsored by Jonsson Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who are undergoing surgery for stage IB, stage II, or stage IIIA non-small cell lung cancer.
Interventions
- PROCEDURE conventional surgery
- PROCEDURE adjuvant therapy
- DRUG autologous tumor cell vaccine
- DRUG therapeutic autologous dendritic cells
- PROCEDURE biological therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2005-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00098917
The ClinicalTrials.gov registry entry for NCT00098917 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which conventional surgery is the first listed.
NCT00098917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00098917 about?
NCT00098917 is a clinical study titled "Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer". RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who are undergoing surgery for stage IB...
What is the current status of trial NCT00098917?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2005-02.
What interventions are being tested in trial NCT00098917?
The interventions under investigation include: conventional surgery (PROCEDURE), adjuvant therapy (PROCEDURE), autologous tumor cell vaccine (DRUG), therapeutic autologous dendritic cells (DRUG), biological therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00098917?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.